Your session is about to expire
← Back to Search
Chemotherapy
Intervention for Pancreatic Cancer (PDAC-LIV Trial)
N/A
Recruiting
Led By Alexandre Brind'Amour, MD, MSc
Research Sponsored by Laval University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 years after surgery
Awards & highlights
PDAC-LIV Trial Summary
This trial is studying a new treatment plan for patients with pancreatic cancer that has spread to the liver. Patients will undergo thorough assessments including blood tests and imaging scans to determine if they are eligible for the study
Who is the study for?
This trial is for patients with pancreatic cancer that has spread to the liver, who have not more than three liver metastases and are deemed operable. They must show a response to FOLFIRINOX chemotherapy as evidenced by imaging and blood tumor markers.Check my eligibility
What is being tested?
The study tests if surgery to remove both the pancreatic tumor and up to three liver metastases after or during cycles of FOLFIRINOX chemotherapy can be beneficial. Patients will undergo detailed scans and receive up to 12 cycles of chemo before and/or after surgery.See study design
What are the potential side effects?
FOLFIRINOX can cause side effects like nausea, vomiting, diarrhea, fatigue, low blood cell counts increasing infection risk, neuropathy (nerve damage), and allergic reactions. Surgical risks include bleeding, infection, pancreatitis.
PDAC-LIV Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 3 years after surgery
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 years after surgery
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Morbidity and mortality
Secondary outcome measures
Overall survival
PDAC-LIV Trial Design
1Treatment groups
Experimental Treatment
Group I: InterventionExperimental Treatment1 Intervention
Patients will undergo surgery for primary pancreatic cancer and liver metastases.
Find a Location
Who is running the clinical trial?
Laval UniversityLead Sponsor
417 Previous Clinical Trials
172,257 Total Patients Enrolled
Alexandre Brind'Amour, MD, MScPrincipal InvestigatorCHU de Québec
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What is the current number of participants being admitted to this clinical study?
"Indeed, the details outlined on clinicaltrials.gov suggest that this investigation is actively seeking suitable participants. This trial was initially registered on January 16th, 2024, and underwent its most recent revision on April 4th of the same year. The research seeks to recruit a total of 15 patients from one designated site."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger